Advertisement
Ingenuity
Ingenuity

HIV Drugs Go Generic

Patent expirations of one HIV drugs will make the disease cheaper—but also more cumbersome—to treat.

By | August 16, 2012

image: HIV Drugs Go Generic Flickr Creative Commons, .v1ctor.

This year, the United States is expected to spend nearly $15 billion on healthcare for HIV patients, which still doesn’t cover all of the patients who need treatment. But those costs are expected to decrease in the next few years as the patents for brand-name antiretrovirals expire.

“AIDS, as we currently know it, may become much more affordable,” John Bartlett, an infectious-disease researcher at Johns Hopkins Bloomberg School of Public Health, told Nature.

The three-in-one antiretroviral Atripla is considered the go-to first line therapy for HIV and is made up of two drugs made by Gilead Sciences and one by Bristol-Myers Squibb (BMS). While only one component from this cocktail, BMS’s efavirenz, will go off patent next year, a second component already has a readily available generic substitute. The cost saving from these two drugs is estimated to save $920 million in the first year.

Although it will be more cumbersome for patients to take three pills per day instead of one, and as a result, they might be more likely to forget or skip doses, most advocates agree that that giving more people access to the medication is worth the trade-off.

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Angelise Evony

Angelise Evony

Posts: 1457

August 16, 2012

This isn't the big news. The big news is that so much funding is spent to combat a disease that affects a very small niche portion of the population. I guess it's true what they say though, the squeaky wheel gets the most grease. :(

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
The Scientist
The Scientist
Advertisement
NeuroScientistNews
NeuroScientistNews
Life Technologies